Testing Status of AZT + Rifampin (AIDS Initiative) M930017

 

CASRN: AZTRIFAMPIN

Secondary:

  • 30516-87-1 - 3'-Azido-3'-deoxythymidine (AIDS)
  • 30516-87-1 - AZT transplacental carcinogenesis study
  • 13292-46-1 - Rifampin

Known Uses

Drug combination to be used as AIDS therapy

Short-Term Toxicity

  • 13 weeks (Gavage)  (C93002)  Completed 
    • Mice: B6C3F1

Special Studies

  • Toxicokinetic Study (Gavage; Intravenous)  (S0553)  Completed 
    • Male and Female Mice: B6C3F1
    • Dose: IV: 100 MG AZT/KG BW; PO: 200 MG AZT/KG BW & 200 MG AZT + 200 MG RIFAMPIN/KG BW Repeated dose study: all doses for AZT and RIF are 100 mg/kg BW.
  • Toxicokinetic Study (Gavage; Intravenous)  (S0643)  Completed 
    • Citation: The Effect of Multiply Administered Rifampicin (RIF) on the Toxicokinetics and Metabolism of 3'-Azido-Deoxythymidine (AZT) in Male and Female B6C3F1 Mice.
    • Male and Female Mice: B6C3F1
    • Dose: AZT: 100 mg/kg Rif: 100 mg/kg.